Sprint Bioscience AB (publ) (SPRINT.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 3.41 (-1.16%) as of
Key statistics
- Market cap
- 359.81M
- P/E (TTM)
- 4.87
- Forward P/E
- 2.62
- EPS (TTM)
- 0.7000
- Dividend yield
- 0.00%
- 52-week range
- 0.5780 – 4.5900
- Beta
- -0.57
- Revenue (TTM)
- 139.36M
- Profit margin
- 54.29%
- Analyst target
- SEK 5.10
- Volume
- 102.61k
About Sprint Bioscience AB (publ)
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases. It is also developing STK25, which is in preclinical trial to treat metabolic liver disease that can lead to inflammation and fibrosis; and TREX1, which is in preclinical trial for the treatment of solid tumors and immuno-oncology. The company has a research collaboration with the Experimental Drug Development Centre for expansion of metabolic dysfunction-associated steatohepatitis programme into inflammatory diseases and evaluation of the STK25 program. The company was incorporated in 2009 and is headquartered in Huddinge, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Huddinge, Sweden
- Employees
- 32
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.